---
schema_version: "secwatch.filing_event.v1"
accession: "0001798749-24-000014"
form_type: "8-K"
ticker: "JBIO"
cik: "0001798749"
company_name: "Jade Biosciences, Inc."
filed_at: "2024-03-25T23:59:59+00:00"
generated_at: "2026-06-04T08:35:36.922571+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aerovate reports 2023 net loss $75.5M; Phase 2b topline data for AV-101 in PAH expected June 2024

## Summary
- Cash, cash equivalents and short-term investments totaled $122.4M at Dec 31, 2023; cash runway expected into 2026.
- Net loss for 2023 was $75.5M compared to $51.5M in 2022; R&D expenses rose to $64.2M from $38.6M.
- Phase 2b portion of IMPAHCT trial enrolled 202 patients; topline data expected in June 2024.
- First patient enrolled in Phase 3 portion of IMPAHCT in November 2023; over 120 clinical sites participating.
- Board expanded with Habib Dable and Donald Santel; Dable appointed Chair in March 2024.

## SEC filing metadata
- accession: 0001798749-24-000014
- form_type: 8-K
- ticker: JBIO
- cik: 0001798749
- company_name: Jade Biosciences, Inc.
- filed_at: 2024-03-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1798749/000179874924000014/0001798749-24-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1798749/000179874924000014/tmb-20240325x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001798749-24-000014
- JSON: https://secwatch.observer/filing/0001798749-24-000014.json
- Plain text: https://secwatch.observer/filing/0001798749-24-000014.txt

## Key facts
- Earnings Releases
  Jade Biosciences, Inc. reported the year ended December 31, 2023 results: net income $75.5 million.
  - Period: the year ended December 31, 2023
  - Net income: $75.5 million
  - Result: reported results
  source text: Net loss for the year ended December 31, 2023 was $75.5 million as compared to $51.5 million for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1798749/000179874924000014/0001798749-24-000014-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.